By The ASCO Post Staff Posted: 8/5/2022 11:35:00 AM Last Updated: 8/5/2022 11:04:31 AM Investigators have identified genetic signatures that could predict whether tumors in patients with bladder and other cancers will respond to immunotherapy with immune checkpoint inhibitors. Their findings, published by…
Olivier Elemento, PhD, Director of the Englander Institute for Precision Medicine (EIPM) at Weill Cornell Medicine, New York, recently announced that Bishoy M. Faltas, MD,…
Researchers identified risk factors for osteoradionecrosis of the jaw and developed a classification system for the condition in patients receiving radiation therapy for head and…
An investigational positron-emission tomography (PET) imaging agent, gallium-68–DPI-4452, offered rapid and accurate visualization of lesions in patients with clear cell renal cell carcinoma.
In an analysis of data from the PORTEC-1, -2, and -3 trials, older age was found to be associated with more aggressive tumor features and…
Researchers have identified novel biomarkers in renal cell carcinoma subtypes, according to a new study. The findings may help identify therapeutic targets in non–clear cell…
Investigators have examined the historical evolution of Community Outreach and Engagement initiatives at the National Cancer Institute (NCI) and NCI-designated cancer centers and provided recommendati…
Results from an NRG Oncology/GOG trial showed “excellent” progression-free survival outcomes with radiation therapy alone for local recurrences of endometrial cancer, with the addition of…
In a retrospective cohort study, patients with breast cancer with nodal downstaging after neoadjuvant chemotherapy had a low rate of axillary recurrence, with no difference…
A patient-reported outcome (PRO) analysis from the phase III TOPAZ-1 trial showed no “detrimental effect” with the addition of durvalumab to gemcitabine/cisplatin in patients with…
Adding the phosphatidylserine-targeting antibody bavituximab to the immunotherapy agent pembrolizumab may improve response rates without compromising safety in patients with hepatocellular carcinoma, …
